RBC Capital Markets

Bluebird Bio CEO snares 24 million pay package as gene therapy advance

Pharma

Nods for two gene therapies 'absolutely critical' for bluebird

In its Q4 earnings report, bluebird bio said that its cash needs raise doubt about its ability to continue as a business in 2022.

Kevin Dunleavy Mar 7, 2022 9:22am

Bottle and box for Aduhelm Biogen Alzheimers medicine

Aduhelm still has big sales potential, RBC doctors' survey says

Mar 3, 2022 2:00pm